I propose to take Questions Nos. 1024 to 1027, inclusive, together.
The HSE estimates that expenditure in 2012 on drugs and non-drug items (dressings, etc.) under the GMS and community drug schemes, including mark ups and dispensing fees will be approximately €1.7 billion. In addition, about €300m will be spent on drugs and medicines used in public hospitals. The HSE estimates that the cost of new drugs in 2012 will be approximately €15 million. Examples include the cancer drug, ipilimumab, and the hepatitis C drugs, boceprevir and teleprevir. The cost of new drugs between 2013 and 2015 is estimated to be approximately €70 million per annum. It is estimated that the recent agreement with the Irish Pharmaceutical Healthcare Association (IPHA) will generate gross savings of up to €116m in 2013. However, the net savings will be affected by the cost of new drugs and by any significant increase in the volume of drugs consumed under the community drugs schemes.